Benzinga - by Lisa Levin, Benzinga Editor.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
Altria Group, Inc. (NYSE: MO)
- Dividend Yield: 9.15%
- Morgan Stanley analyst Pamela Kaufman reiterated an Equal-Weight rating with a price target of $45 on July 18, 2023. This analyst has an accuracy rate of 65%.
- Citigroup analyst Adam Spielman maintained a Neutral rating and slashed the price target from $49.5 to $47 on April 17, 2023. This analyst has an accuracy rate of 63%.
- Recent News: Altria Group reported second-quarter FY23 Revenues net of excise taxes growth of 1.2% to $5.438 billion, marginally missing the analyst consensus of $5.45 billion.
- Dividend Yield: 8.91%
- Truist Securities analyst David Macdonald reiterated a Hold rating with a price target of $30 on Sept. 5, 2023. This analyst has an accuracy rate of 68%.
- Mizuho analyst Ann Hynes reiterated a Neutral rating with a price target of $31 on July 14, 2023. This analyst has an accuracy rate of 72%.
- Recent News: Walgreens recently announced CEO Rosalind Brewer will step down and also said it expects FY23 adjusted EPS to be at or near the low end of its previously stated range.
- Dividend Yield: 8.04%
- DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating and cut the price target from $93 to $80 on Aug. 8, 2023. This analyst has an accuracy rate of 68%.
- Jefferies analyst Stephanie Wissink downgraded the stock from Buy to Hold and slashed the price target from $345 to $150 on Aug. 4, 2022. This analyst has an accuracy rate of 81%.
- Recent News: Medifast posted better-than-expected second-quarter financial results.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.